ArticleACR open rheumatology2026
International Myositis Assessment and Clinical Studies Guidelines for Risk-Based Cancer Screening: An External Validation in Patients With Dermatomyositis Seen at a Metropolitan Academic Center.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) characterized by muscle weakness, skin findings, and increased malignancy risk. Cancer risk is greatest in the three years before or after DM onset, termed paraneoplastic DM. The International Myositis Assessment and Clinical Studies Group (IMACS) set forth evidence-based guidelines for risk stratification and cancer screenings for newly diagnosed patients with IIM.
methodsWe retrospectively reviewed the records of 413 patients with a known diagnosis of DM or clinically amyopathic DM at the Mount Sinai Health System (2019-2024). Demographics, clinical findings, laboratory results, myositis autoantibody panels, and cancer screening or diagnosis data were collected.
resultsAmong the 413 patients with DM, 6.5% (n = 27) had paraneoplastic DM. The proportion of paraneoplastic disease was highest in the high-risk group (8.8%), compared to intermediate- (5.1%) and low-risk (2.5%) groups. 70.4% of patients with paraneoplastic DM were categorized as high risk, compared to 51% of nonparaneoplastic patients. Among the intermediate-risk patients, most patients were diagnosed with cancer more than one year after DM diagnosis. Age ≥40 at DM diagnosis was statistically significant for an increased risk of paraneoplastic DM (P = 0.001). The most common paraneoplastic malignancies were breast cancer and lung cancer. One-third of patients with paraneoplastic DM were diagnosed with cancer within three years preceding DM diagnosis.
conclusionThe IMACS screening guidelines and risk stratification showed moderate sensitivity for identifying paraneoplastic DM, helping to identify a majority of patients at the highest risk for malignancy leading to more targeted and risk-based screening.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.